Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Survey of Clinical Practice of Adjuvant Treatment of Breast Cancer Using Exemestane (Aromasin?) in Postmenopausal Hr+ Patients.

Next Previous
Search
Trial Profile

A Survey of Clinical Practice of Adjuvant Treatment of Breast Cancer Using Exemestane (Aromasin?) in Postmenopausal Hr+ Patients.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exemestane (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Acronyms ETAPE
  • Sponsors Pfizer

Most Recent Events

  • 30 Nov 2011 Planned end date changed from 1 Feb 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
  • 30 Nov 2011 Actual patients number changed from 392 to 398 as reported by ClinicalTrials.gov.
  • 24 Mar 2011 Planned end date changed from 1 Feb 2011 to 1 Dec 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top